2a:I[856015,["/_next/static/immutable/chunks/1xzisbplk9czp.js","/_next/static/immutable/chunks/3j2i1faptc_-9.js","/_next/static/immutable/chunks/3ne0dxjrpj6b3.js","/_next/static/immutable/chunks/08tq8rmv423j5.js","/_next/static/immutable/chunks/25k7ikgmcage7.js","/_next/static/immutable/chunks/32zk736rs0hqw.js","/_next/static/immutable/chunks/0lbgs964whs_0.js","/_next/static/immutable/chunks/1a_hqhrsle_n_.js","/_next/static/immutable/chunks/0hcnvyarhzl7i.js"],"default"] 2b:T7662,

Summary Table

Feature	Opioid Intoxication	Opioid Withdrawal
Risk Factors	IV drug use, prescription opioid misuse, chronic pain patients on escalating doses, post-incarceration or post-rehab relapse (lost tolerance)	Abrupt cessation of chronic opioid use, admission to hospital/jail without continuation, naloxone administration
Etiology	Excessive mu-opioid receptor agonism leading to CNS and respiratory depression	Rebound noradrenergic hyperactivity from the locus coeruleus after removal of chronic opioid suppression
Patient Presentation	Found unresponsive, slow or absent breathing, "won't wake up"	"Feels like the worst flu of my life," restless, anxious, diffuse body aches, cannot sleep
Classic Physical Exam	Pinpoint pupils (miosis), respiratory depression, decreased level of consciousness, hypotension, hypothermia, decreased bowel sounds	Dilated pupils (mydriasis), lacrimation, rhinorrhea, yawning, piloerection ("gooseflesh"), diaphoresis, hyperactive bowel sounds, tachycardia
Key Diagnostic Results	Urine drug screen positive for opioids; ABG showing respiratory acidosis with elevated $PaCO_2$	Clinical diagnosis; Clinical Opiate Withdrawal Scale (COWS) score to quantify severity
Management	Naloxone (opioid antagonist) IV/IM/IN; airway support	Buprenorphine-naloxone or methadone for medication-assisted treatment; clonidine for symptomatic relief
Keywords	"Pinpoint pupils," "found unresponsive," "respiratory rate of 6," "needle track marks," "responded to naloxone"	"Gooseflesh," "flu-like symptoms in a known opioid user," "yawning and tearing," "diarrhea and cramping after stopping medication," "pupils dilated"

1. Pathophysiology

Opioids exert their effects by binding to mu (μ), kappa (κ), and delta (δ) receptors throughout the central and peripheral nervous systems. The mu receptor is the most clinically relevant for both the desired analgesic effects and the dangerous toxicity profile. When opioids bind to mu receptors in the brainstem, they suppress the medullary respiratory center, directly reducing the brain's sensitivity to rising $CO_2$ levels. This is the mechanism behind respiratory depression, which is the primary cause of death in opioid overdose.

Miosis (pinpoint pupils) occurs because opioids stimulate the Edinger-Westphal nucleus of the oculomotor nerve (cranial nerve III), causing parasympathetic-driven pupillary constriction. This finding persists even in deep coma and is one of the most reliable exam clues. Decreased bowel motility results from opioid binding to mu receptors in the myenteric plexus of the gastrointestinal tract, reducing peristalsis and explaining the classic constipation.

In withdrawal, the pathophysiology is essentially the mirror image. During chronic opioid use, the locus coeruleus (the brain's primary noradrenergic nucleus) is tonically suppressed by opioid input. The neurons compensate by upregulating cyclic AMP (cAMP) pathways and increasing their baseline activity level. When opioids are abruptly removed, this compensatory hyperactivity is unmasked, producing a surge of norepinephrine release. This noradrenergic storm explains the sympathetic-dominant symptoms: tachycardia, hypertension, diaphoresis, mydriasis, piloerection, and anxiety. The gastrointestinal tract, similarly released from opioid suppression, rebounds with hyperactive motility, causing cramping, nausea, vomiting, and diarrhea.

A critical concept for the exam: opioid withdrawal is intensely uncomfortable but not life-threatening in otherwise healthy adults. This stands in direct contrast to alcohol and benzodiazepine withdrawal, which can cause seizures and death. This distinction is frequently tested.

2. Classification and Clinical Manifestation

Opioid Intoxication

Severity	Mental Status	Respiratory Findings	Pupil Size	Other Signs
Mild	Drowsy but arousable	RR 10-12/min, adequate $SpO_2$	Miotic	Slurred speech, nausea
Moderate	Somnolent, responds to stimulation	RR 8-10/min, decreasing $SpO_2$	Pinpoint	Hypotension, decreased reflexes
Severe (Overdose)	Unresponsive, coma	RR < 8/min or apnea, cyanosis	Pinpoint (may dilate if anoxic brain injury occurs)	Pulmonary edema (non-cardiogenic), needle track marks, hypothermia

Opioid Withdrawal Timing

Feature	Short-Acting Opioids (heroin, morphine, oxycodone)	Long-Acting Opioids (methadone)
Onset after last dose	6 to 12 hours	24 to 48 hours
Peak symptoms	36 to 72 hours	72 to 96 hours
Duration	5 to 7 days	14 to 21 days

Opioid Withdrawal Symptoms

Phase	Timing	Symptoms
Early	6 to 24 hours	Anxiety, yawning, lacrimation, rhinorrhea, diaphoresis, restlessness
Intermediate	24 to 48 hours	Mydriasis, piloerection, myalgias, arthralgias, anorexia, irritability
Late/Peak	48 to 72 hours	Nausea, vomiting, abdominal cramping, diarrhea, tachycardia, hypertension, insomnia, muscle spasms

Neonatal Abstinence Syndrome (NAS)

Feature	Details
Population	Neonates born to mothers with chronic opioid use
Onset	Within 24 to 72 hours of birth (may be delayed to 5 to 7 days for methadone)
Key findings	High-pitched cry, tremors, irritability, poor feeding, sneezing, diarrhea, seizures in severe cases
Management	Supportive care first; morphine or methadone taper if severe; use Finnegan Scoring System

3. Diagnostic Workup

Test	Purpose	Role	Key Findings
Urine drug screen (UDS)	Detect opioid metabolites	Best initial test for confirming opioid exposure	Positive for opioids; note that synthetic opioids (fentanyl, methadone) may not appear on standard immunoassay panels
Arterial blood gas (ABG)	Assess ventilatory status in intoxication	Adjunct in overdose	Respiratory acidosis: elevated $PaCO_2$, decreased pH, low $PaO_2$
Serum lactate	Assess tissue perfusion in severe overdose	Prognostic marker	Elevated if prolonged hypoxia or circulatory compromise
Clinical Opiate Withdrawal Scale (COWS)	Quantify withdrawal severity	Standard assessment tool for withdrawal	Score 5-12 = mild; 13-24 = moderate; 25-36 = moderately severe; >36 = severe
ECG	Screen for QTc prolongation	Required before starting methadone	Prolonged QTc is a contraindication to methadone initiation or dose increase
Chest X-ray	Evaluate for non-cardiogenic pulmonary edema	Adjunct in overdose with hypoxia despite naloxone	Bilateral infiltrates without cardiomegaly

For opioid intoxication, the diagnosis is primarily clinical. The classic triad of altered mental status + respiratory depression + miosis in a patient with risk factors (track marks, drug paraphernalia at the scene, known opioid use) should immediately suggest the diagnosis. A urine drug screen serves as confirmation, but treatment with naloxone should never be delayed while waiting for lab results. In practice, a dramatic response to naloxone is itself considered diagnostic. Be aware that synthetic opioids like fentanyl and its analogs frequently do not register on standard immunoassay-based urine drug screens, which test primarily for morphine metabolites. If the clinical picture strongly suggests opioid overdose but the UDS is negative, fentanyl should be suspected, and the clinical diagnosis stands.

An ABG is obtained in patients with significant respiratory depression to quantify the degree of hypoventilation. The expected pattern is a primary respiratory acidosis (low pH, elevated $PaCO_2$) reflecting the central suppression of ventilatory drive.

For opioid withdrawal, the diagnosis is entirely clinical. There is no confirmatory laboratory test. The COWS score is the standard validated instrument used to objectively measure withdrawal severity and guide treatment decisions. A COWS score of 5 to 12 indicates mild withdrawal, while scores above 36 indicate severe withdrawal. Importantly, buprenorphine should generally not be initiated until the COWS score reaches at least 8 to 12 to avoid precipitating worse withdrawal (discussed further below).

Before initiating methadone maintenance, an ECG must be obtained because methadone is associated with QTc prolongation and risk of torsades de pointes. This is a frequently tested association.

4. Management and Treatment

Opioid Intoxication Management

Step	Intervention	Details
1. Airway and breathing	Basic life support, bag-valve-mask ventilation	Always secure the airway first; naloxone is not a substitute for ventilatory support
2. Naloxone	0.04 to 0.4 mg IV initially in known opioid-dependent patients; 0.4 to 2 mg IV in non-dependent patients	Repeat every 2 to 3 minutes as needed; maximum dose up to 10 mg
3. Observation	Monitor for re-sedation	Naloxone half-life (30 to 90 min) is shorter than most opioids; redosing or continuous infusion may be needed
4. Continuous infusion	Naloxone drip at two-thirds of the effective bolus dose per hour	Used when repeated boluses are required or with long-acting opioids (methadone, extended-release formulations)
5. Adjuncts	Treat pulmonary edema with positive-pressure ventilation; treat hypothermia with rewarming	Non-cardiogenic pulmonary edema does not respond to diuretics

Naloxone is a competitive mu-opioid receptor antagonist that rapidly reverses respiratory depression. The critical exam concept is that naloxone has a shorter duration of action (30 to 90 minutes) than nearly all opioids it is used to reverse. This means that after the naloxone wears off, the patient can lapse back into respiratory depression and die. For this reason, all patients who receive naloxone must be observed for a minimum of 4 to 6 hours, and longer if a long-acting opioid was involved.

In patients who are known to be opioid-dependent, start with a lower dose of naloxone (0.04 to 0.1 mg IV) and titrate upward. The goal is to restore adequate respiration (respiratory rate above 12, adequate oxygen saturation) without fully reversing analgesia, which would precipitate acute withdrawal (extremely distressing but not lethal in adults). Precipitated withdrawal in a pregnant opioid-dependent patient can cause fetal distress, placental abruption, or fetal death, making cautious naloxone dosing especially important in this population.

If the patient does not respond to a total of 10 mg of naloxone, the diagnosis of pure opioid intoxication should be reconsidered. Look for co-ingestants (benzodiazepines, alcohol, barbiturates) or alternative diagnoses (pontine hemorrhage, hypoglycemia).

Opioid Withdrawal Management

Approach	Drug	Dose and Route	Key Notes
Medication-assisted treatment (preferred)	Buprenorphine-naloxone (Suboxone)	Sublingual; start 2 to 4 mg when COWS ≥ 8-12; titrate up to 16 to 24 mg/day	Partial mu-agonist; has a ceiling effect on respiratory depression; must wait until patient is in moderate withdrawal to avoid precipitated withdrawal
Medication-assisted treatment (preferred)	Methadone	Oral; start 20 to 30 mg/day; titrate by 5 to 10 mg every 3 to 5 days; typical maintenance 60 to 120 mg/day	Full mu-agonist; requires QTc monitoring; dispensed only through licensed opioid treatment programs (OTPs); preferred in pregnancy
Symptomatic adjuncts	Clonidine	0.1 to 0.3 mg PO every 6 to 8 hours	Alpha-2 agonist; reduces noradrenergic hyperactivity; treats tachycardia, hypertension, diaphoresis, anxiety; monitor for hypotension
	Loperamide	4 mg initially, then 2 mg after each loose stool (max 16 mg/day)	For diarrhea
	Dicyclomine or hyoscyamine	As directed	For abdominal cramping
	NSAIDs (ibuprofen)	400 to 600 mg PO every 6 to 8 hours	For myalgias and arthralgias
	Ondansetron	4 to 8 mg PO/IV every 8 hours	For nausea and vomiting

The most important management concept is the distinction between medication-assisted treatment (MAT) and symptom-only approaches. Current guidelines strongly favor MAT with either buprenorphine-naloxone or methadone, as these significantly reduce relapse and mortality. Symptomatic treatment alone (clonidine plus supportive medications) is considered inferior and is used only when MAT is unavailable or declined.

Buprenorphine is a partial mu-agonist with a ceiling effect on respiratory depression, making it safer than methadone in many contexts. However, because it has very high receptor affinity but lower intrinsic activity than full agonists, administering it too early (while full agonists are still occupying receptors) will displace those agonists and trigger precipitated withdrawal. This is why buprenorphine must not be given until the patient is in established withdrawal (COWS score of at least 8 to 12).

Methadone is the preferred agent for pregnant patients with opioid use disorder because it provides stable opioid levels and prevents the fetal stress associated with repeated withdrawal cycles. Buprenorphine (as monotherapy without naloxone) is an acceptable alternative in pregnancy. The key point: never attempt medically unsupervised detoxification in a pregnant patient, as withdrawal can be fatal to the fetus even though it is not fatal to the mother.

Clonidine works by stimulating presynaptic alpha-2 adrenergic receptors in the locus coeruleus, dampening the noradrenergic surge that drives withdrawal symptoms. It does not reduce cravings and is therefore only an adjunct, not a standalone treatment.

For long-term relapse prevention after detoxification is complete, naltrexone (extended-release intramuscular injection, 380 mg monthly) is an option. It is a long-acting opioid antagonist that blocks the euphoric effects of opioids. Naltrexone requires the patient to be fully detoxified (7 to 10 days opioid-free) before initiation; otherwise, it will precipitate withdrawal.

5. Differential Diagnosis and Distractors

Opioid Intoxication

Differential	Why It Is Similar	Key Discriminator
Benzodiazepine overdose	Also presents with CNS depression, somnolence, respiratory depression	Pupils are normal or slightly dilated (not pinpoint); does not respond to naloxone; responds to flumazenil
Barbiturate overdose	CNS depression, respiratory failure, hypotension	Pupils may be mid-position or dilated; no response to naloxone; often shows bullous skin lesions ("barb burns")
Pontine (brainstem) hemorrhage	Can produce pinpoint pupils and coma, mimicking the opioid triad	Focal neurological deficits (posturing, absent corneal reflexes, gaze palsies); no response to naloxone; CT head reveals hemorrhage
Clonidine overdose	Miosis, bradycardia, CNS depression, hypotension	More prominent bradycardia and hypotension; history of hypertension medication; does not respond to naloxone
Hypoglycemia	Altered mental status, diaphoresis, found unresponsive	Pupils are normal; rapid bedside glucose is low; responds to dextrose, not naloxone

Opioid Withdrawal

Differential	Why It Is Similar	Key Discriminator
Influenza or viral gastroenteritis	Myalgias, rhinorrhea, nausea, vomiting, diarrhea	No mydriasis or piloerection; no history of opioid use; normal pupils; no drug-seeking behavior
Sympathomimetic intoxication (cocaine, amphetamines)	Tachycardia, hypertension, mydriasis, diaphoresis, agitation	History of stimulant use, not opioid cessation; often with hyperthermia and psychomotor agitation out of proportion; may have chest pain
Alcohol withdrawal	Anxiety, tachycardia, diaphoresis, tremor, insomnia	Risk of seizures and delirium tremens (which opioid withdrawal does not cause); history of alcohol rather than opioid use; visual hallucinations
Anticholinergic toxidrome	Mydriasis, tachycardia, agitation	Dry skin and mucous membranes ("dry as a bone"), decreased bowel sounds, urinary retention; opioid withdrawal produces wet symptoms (diaphoresis, rhinorrhea, diarrhea)
Serotonin syndrome	Mydriasis, diaphoresis, tachycardia, agitation	Clonus, hyperreflexia, and hyperthermia are prominent; history of serotonergic drug use or recent dose change

6. Traps and High-Yield Pearls

The most common way students lose points on opioid questions is by confusing the pupil findings: miosis for intoxication, mydriasis for withdrawal. When a vignette describes a patient with "pinpoint pupils," the answer is always pointing toward opioid intoxication or a pontine lesion, never withdrawal. Conversely, when a patient has dilated pupils with "flu-like" symptoms and a history of drug use, think withdrawal.

The second classic trap involves naloxone duration. Students correctly identify that naloxone is the treatment for overdose but forget that its half-life is much shorter than the opioid it is reversing. Vignettes will describe a patient who "improves after naloxone administration" and then ask what the next step is. The answer is not discharge; it is extended observation with possible continuous naloxone infusion, because re-sedation and fatal respiratory depression can occur once the naloxone wears off.

A third high-yield trap is precipitated withdrawal with buprenorphine. A vignette may describe a patient in early withdrawal (COWS score of 3 or 4) who is given buprenorphine and acutely worsens. Students must understand that buprenorphine, as a high-affinity partial agonist, will displace remaining full agonists from receptors and worsen withdrawal if given too early.

Students also frequently miss the methadone-QTc association. Any question that involves starting methadone maintenance should prompt you to think about ordering a baseline ECG. If the QTc is prolonged, methadone is not the right choice.

Finally, remember that opioid withdrawal is never fatal in a healthy adult but can be fatal to a fetus. A question about a pregnant woman with opioid use disorder who wants to "just stop using" should lead you toward recommending maintenance therapy (methadone or buprenorphine monotherapy), not abrupt cessation.

The core competency being tested across all opioid questions is pattern recognition of two opposing clinical pictures (intoxication vs. withdrawal), appropriate pharmacologic intervention, and understanding the pharmacokinetic pitfalls that lead to clinical deterioration after initially correct treatment.

1b:["$","$L2a",null,{"article":{"id":"4cd61c0d-5a25-49d5-9693-abbd7b97a48e","title":"Opioid","content":"$2b","category":"Psikiatri","created_at":"2026-09-05T00:22:57.622226+00:00","status":"published","subcategory":null},"questionCount":0,"sections":[{"id":"section-pathophysiology","num":"01","title":"Pathophysiology"},{"id":"section-classification-and-clinical-manifestation","num":"02","title":"Classification and Clinical Manifestation"},{"id":"section-diagnostic-workup","num":"03","title":"Diagnostic Workup"},{"id":"section-management-and-treatment","num":"04","title":"Management and Treatment"},{"id":"section-differential-diagnosis-and-distractors","num":"05","title":"Differential Diagnosis and Distractors"},{"id":"section-traps-and-high-yield-pearls","num":"06","title":"Traps and High-Yield Pearls"}],"hasSummaryTable":true}]